Alnylam Pharmaceuticals, Inc.
ALNYStock
$283.15−10.28%52W
Market Cap$37.17B
P/E118.46x
Div yield—
Beta0.24
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-43.39%
Price vs S&P 500 (4W)-1.58%
VGM Score46.23
Market Capitalization$37.17B
P/E Ratio (Annual)118.46x
Earnings Surprise History
Q1 261.51est. 0.96
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
3.94
3.94
3.95
3.97
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ALNYAlnylam Pharmaceuticals, Inc. | D | A | D | $283.15 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapeutics with five FDA-approved drugs generating revenue across rare genetic diseases and cardio-metabolic indications. The company has an expanding pipeline in genetic medicines, hepatic infectious diseases, and CNS/ocular diseases, with multiple programs in clinical development. Partnership upfront fees and upcoming milestone and royalty payments from collaborations provide additional cash generation and revenue diversification beyond its commercial portfolio.